biotech / news / / CNBC
Eli Lilly's retatrutide works differently from existing shots and pills.
Eli Lilly's retatrutide achieved up to 28.3% weight loss over 80 weeks in late-stage obesity trial.
KEY POINTS
- A 4-milligram dose of retatrutide caused only 4% discontinuation due to side effects, lower than placebo.
- Retatrutide showed no observed cardiac or liver safety issues, addressing prior analyst concerns.
- Higher rates of urinary tract infections were noted at the highest dose, but were generally mild.
- 45% of trial participants on the highest retatrutide dose lost 30% or more of their body weight.
COMPANIES
Summarized by Newsio from CNBC. How we summarize →